Alterations in Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis: Findings from 16S rRNA Sequencing and Untargeted Metabolomics Analysis - Scorecard - MDSpire
Advertisement
Alterations in Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis: Findings from 16S rRNA Sequencing and Untargeted Metabolomics Analysis
Clinical Scorecard: Alterations in Gut Microbiota and Metabolomic Profiles in Myasthenia Gravis: Findings from 16S rRNA Sequencing and Untargeted Metabolomics Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Autoimmune disorder affecting neuromuscular transmission, associated with gut dysbiosis (e.g., depletion of Faecalibacterium prausnitzii) and metabolic disturbances.
Target Population
Care Setting
Key Highlights
MG patients exhibit reduced gut microbiota diversity and altered metabolomic profiles, including specific metabolites like lithocholic acid.
Identification of 232 discriminative microbial taxa and 567 altered metabolites in MG, with clinical correlations.
Positive correlations found between specific metabolites (e.g., lithocholic acid) and clinical severity scores.
Guideline-Based Recommendations
Diagnosis
Management
Long-term immunosuppressive therapy is the cornerstone of MG management.
Consider adjunct therapies targeting gut microbiota.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Immunosuppressive therapy remains essential for achieving minimal disease manifestation; the control group provides a baseline for comparison.
Clinical Best Practices
Integrate gut microbiota and metabolomic profiling in MG for potential diagnostic biomarkers.
Monitor gut health as part of comprehensive MG management strategies, including dietary interventions.
Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.
